title: Hedgehog signaling pathway in ovarian cancer.
abstract: Despite advances in surgical and chemotherapeutic treatment options, less than 50% of patients with advanced-stage ovarian cancer survive five years after initial diagnosis. In this regard, novel treatment approaches are warranted utilizing molecularly targeted therapies directed against particular components of specific signaling pathways which are required for tumor development and progression. One molecular pathway of interest is the hedgehog (Hh) signaling pathway. Activation of the Hh pathway has been observed in several cancer types, including ovarian cancer. This review highlights the crucial role of Hh signaling in the development and progression of ovarian cancer and might lead to a better understanding of the Hh signaling in ovarian tumorigenesis, thus encouraging the investigation of novel targeted therapies.
authors.affiliation: Division of Clinical Oncology, Department of Medicine, Medical University of Graz, 8036 Graz, Austria. martin.pichler@medunigraz.at.
authors.forename: Joanna
authors.initials: J
authors.lastname: Szkandera
authors.forename: Tobias
authors.initials: T
authors.lastname: Kiesslich
authors.forename: Johannes
authors.initials: J
authors.lastname: Haybaeck
authors.forename: Armin
authors.initials: A
authors.lastname: Gerger
authors.forename: Martin
authors.initials: M
authors.lastname: Pichler
mesh_terms: D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000378:metabolism*; D018450:Disease Progression; D005260:Female; D053823:Hedgehog Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006801:Humans; D008954:Models, Biological; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D015398:Signal Transduction
chemical_list: D053823:Hedgehog Proteins